Stem Cell Microparticles for Targeted NK Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods have not effectively utilized exosomes derived from mesenchymal stem cells to control the expression of specific microRNAs for activating NK cells, which are crucial for enhancing their activity, particularly in addressing age-related declines and stress-induced deterioration.
Innovation Solution
Microparticles containing miRNA, specifically hsa-miR-155-5p, derived from the culture supernatant of dental pulp-derived or adipose-derived stem cells, are used to control the expression of proteins and genes related to NK cell activation, promoting the production of granzyme B and regulating SHIP1 expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to activate NK cells, then general activation occurs, but specific control of miRNA expression and targeted protein regulation is insufficient
Solution Approach 1:
The patent uses exosomes as intermediary carriers to deliver specific miRNAs (particularly miR-155) to NK cells. These exosomes act as natural delivery vehicles that protect miRNAs from degradation and facilitate their uptake by target cells, enabling precise control of gene expression without complex artificial delivery systems
Solution Approach 2:
The patent changes the chemical and biological parameters of the activation system by introducing specific miRNAs that target key regulatory proteins (such as SHIP1, PTEN, and SOCS1). This allows precise control of signaling pathways through post-transcriptional regulation, achieving specific activation control without complex multi-component systems
2Reliability
If NK cell activity is enhanced through general stimulation, then overall activation increases, but targeted control of specific activation pathways is limited
Solution Approach 1:
The patent extracts and utilizes specific miRNAs (particularly miR-155) from exosomes as the active component for NK cell activation. By isolating and concentrating these specific miRNAs, the method achieves reliable and targeted activation control while simplifying the overall activation approach compared to using complex stimulation mixtures
Solution Approach 2:
Exosomes serve as natural mediators that deliver specific miRNAs to NK cells, enabling reliable activation through a biologically compatible delivery system. This approach is easier to manufacture than synthetic delivery systems while providing targeted control of activation pathways through specific miRNA-protein interactions
3Productivity
If exosomes from mesenchymal stem cells are used to deliver miRNA, then NK cell activation is promoted, but the specific control of miRNA expression and target protein regulation is not fully achieved
Solution Approach 1:
The patent applies local quality by introducing specific miRNAs (particularly miR-155) into exosomes at controlled concentrations. This allows different regions or batches of exosomes to have optimized miRNA content tailored for specific activation purposes, achieving both high productivity and precise control of gene expression in NK cells
Solution Approach 2:
The patent optimizes parameters such as miRNA concentration, exosome purification methods, and delivery conditions to achieve both high NK cell activation efficiency and precise control of miRNA expression. By adjusting these parameters, the method simultaneously improves productivity and manufacturing precision
Data Source
AI summary
Microparticles comprising miRNA with respect to the activation of NK cells and derived from culture supernatant of dental pulp-derived stem cells or culture supernatant of adipose-derived stem cells are new microparticles that enables controlling the expression of proteins and/or genes related to the activation of NK cells; an agent for activating NK cells; a method for culturing NK cells; a method for producing activated NK cells; NK cells; a method for activating NK cells NK cells.